Wall Street Associates’s Iovance Biotherapeutics IOVA Stock Holding History

Wall Street Associates’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-59,847	Closed	-$549K	–	327
2015 Q2	$549K	Sell	59,847 -16,700	-22%	-$186K	0.05%	263
2015 Q1	$927K	Buy	+76,547	New	+$862K	0.09%	215

Other funds holding IOVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Wall Street Associates's IOVA Position: Q3 2015 in Review

Wall Street Associates sold out of Iovance Biotherapeutics (IOVA) in Q3 2015, closing a stake of 59,847 shares — an estimated $549K sold.

Wall Street Associates first reported a position in IOVA in Q1 2015 and held it in 2 quarters. The position peaked at $927K in Q1 2015. 80 funds tracked by Wall St. Rank hold IOVA as of Q3 2015.

Wall Street Associates reported no remaining Iovance Biotherapeutics position as of Q3 2015 after selling out during the quarter.
Wall Street Associates sold 59,847 Iovance Biotherapeutics shares in Q3 2015, an estimated $549K.
Wall Street Associates first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 2 quarters.
Wall Street Associates's Iovance Biotherapeutics position peaked at $927K in Q1 2015.
80 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2015.

Based on Wall Street Associates's 13F filing for Q3 2015, filed 12 Nov 2015.